ebov

EBOV-IN-1 is an adamantane dipeptide piperazine inhibitor against Ebola virus (EBOV) that inhibits EBOV infection and suppresses pseudotypic EBOV infection.

EBOV-IN-C31 is a novel PP1-targeting Ebola Virus (EBOV) inhibitor with improved pharmacological properties.

EBOV-IN-8 (Compound 30) effectively inhibits the Ebola pseudotyped virus (pEBOV) with an inhibition concentration (IC 50) of 62.1% at a dosage of 10 μM [1].

EBOV-IN-5 (compound 14) serves as an antiviral agent targeting the Ebola virus (EBOV) by disrupting its entry mechanism into host cells. It specifically blocks the interaction between the EBOV glycoprotein EBOV-GPcl and the essential host receptor NPC1, which is crucial for the virus's fusion and entry into the cell. [7] [1]

EBOV-IN-3 (compound 9), a benzothiazepine compound, and EBOV-IN-6 exhibit notable anti-pEBOV activity, with the latter demonstrating an IC 50 value of 0.37 μM [1].

EBOV-GP-IN-1 (Compound 28) is a potent inhibitor of Ebola virus entry, targeting the Ebola virus envelope glycoprotein (EBOV-GP) with an IC50 of 0.05 μM.

EBOV-IN-7 (compound 26) acts as an inhibitor against the Ebola virus EBOV, displaying an IC 50 value of 2.04 μM against pEBOV (EBOV-GP pseudotyped virus). It also obstructs the EBOV-GPcl NPC1 interaction and exhibits inhibitory effects on cancer cells. [8] [1]

EBOV-IN-4 (compound 12), a benzothiazepine, acts as a potent inhibitor against the Ebola virus (EBOV), displaying 64.9% inhibitory activity against EBOV-GP-pseudotype virus (pEBOV) at a concentration of 10 μM. It is, however, inactive against ASFV [1].

Cephaeline hydrochloride, a phenolic alkaloid found in Indian Ipecac, effectively inhibits the infection of viruses ZIKV and EBOV.

K777 is a potent, orally active, and irreversible inhibitor of cysteine protease, functioning as a potent CYP3A4 inhibitor (IC50 = 60 nM) and a selective CCR4 antagonist, which inhibits chemotaxis. K777 irreversibly inhibits Cruzain, the major cysteine protease of Trypanosoma cruzi, and cathepsins B and L, targeting cathepsin-mediated cell entry and exhibiting broad-spectrum antiviral activity. It inhibits EBOV and SARS-CoV pseudovirus entry with IC50 values of 0.87 nM and 0.68 nM, respectively.

Toremifene (GTx 006) is a selective estrogen-receptor modulator (SERM).

Retro-2 (2-{[(5-methyl-2-thienyl)methylene]amino}) is a plant toxin ricin inhibitor, itprotects HeLa cells against Ricin, Stx1 and Stx2, selectively blocks retrograde toxin trafficking at the early endosome-TGN (trans-Golgi network) interface.

Cosfroviximab (c13C6-FR1) is a chimeric monoclonal antibody derived from mouse and human sources, designed to target the Ebola virus glycoprotein (EBOV-GP) [1].

SP187 (MON-DNJ) is a host-targeted iminosugar. It has anti-filovirus infection activity.SP187 is used for therapeutic use against influenza and dengue viruses.

Anti-virus agent 1 (compound 4i), a phosphoramidate prodrug of GS-5734, exhibits potent antiviral efficacy and is primarily utilized in coronavirus and Ebola virus (EBOV) research.

matrix protein (3-15) [Zaire ebolavirus] is a peptide of the structural proteins linking the viral envelope with the zaire ebolavirus core. Ebola virus (EBOV) is a member of the family Filoviridae in the order Mononegavirales. It is the causative agent of

CP19, a histamine receptor antagonist, serves as an entry inhibitor for Ebolavirus (EBOV) and Marburgvirus (MARV), with inhibitory concentrations (IC50s) of 3.4 μM for EBOV and 29.5 μM for MARV, and selective index (SI) values of 29.4 for EBOV and 3.4 for MARV, indicating its antiviral activity against these viruses.

Atoltivimab (REGN3470), also known as maftivimab/odesivimab (Inmazeb), represents the first monoclonal antibody approved by the Food and Drug Administration (FDA) to combat Zaire ebolavirus (EBOV) infection [1].

FGI-106 is a potent, broad-spectrum inhibitor demonstrating activity against various viruses, including Ebola, Rift Valley Fever, and Dengue Fever, exhibiting EC50 values of 100 nM, 800 nM, and 400-900 nM, respectively. Furthermore, it effectively inhibits non-hemorrhagic fever viruses such as HCV and HIV-1, with EC50s of 200 nM and 150 nM, respectively.

Eritoran, a Toll-like receptor 4 (TLR4) antagonist, effectively protects mice from lethal infections caused by viruses such as the Ebola virus (EBOV) and Marburg virus (MARV). By decreasing granulocytosis levels, Eritoran may reduce the severity of cytokine storms, thereby inhibiting the pathogenesis of filovirus infections [1].

FGI-106 tetrahydrochloride demonstrates potent inhibitory activity across a broad spectrum of viruses, including those causing hemorrhagic fevers such as Ebola, Rift Valley, and Dengue Fever, with half-maximal effective concentrations (EC50s) of 100 nM, 800 nM, and 400-900 nM, respectively. Additionally, it effectively inhibits non-hemorrhagic fever viruses, notably HCV and HIV-1, with EC50s of 200 nM and 150 nM, respectively, indicating its broad-spectrum antiviral potential.

ZINC32540717 is a potent ebolavirus (EBOV) inhibitor.

ZINC09410451 is a potent ebolavirus (EBOV) inhibitor.

(-)-Cephaeline (dihydrochloride) is an enantiomer of Cephaeline. Cephaeline is a selective CYP2D6 inhibitor (IC50: 121 μM).

Cephaeline was highly active against protected primary CLL cells (relative IC50's 35nM ) and acted by repressing HIF-1α± and disturbing intracellular redox homeostasis.

Cephaeline dihydrobromide is a useful organic compound for research related to life sciences and the catalog number is T124574.